中国中西医结合急救杂志
中國中西醫結閤急救雜誌
중국중서의결합급구잡지
INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE IN PRACTICE OF CRITICAL CARE MEDICINE
2013年
2期
89-91
,共3页
金海丽%王孙尧%梅淑芬%詹璐
金海麗%王孫堯%梅淑芬%詹璐
금해려%왕손요%매숙분%첨로
孟鲁司特%支原体%慢性咳嗽%嗜酸粒细胞阳离子蛋白%白细胞介素
孟魯司特%支原體%慢性咳嗽%嗜痠粒細胞暘離子蛋白%白細胞介素
맹로사특%지원체%만성해수%기산립세포양리자단백%백세포개소
Montelukast%Mycoplasma%Chronic cough%Eosinophil cationic protein%Interleukin
目的观察孟鲁司特治疗儿童支原体感染致慢性咳嗽的临床疗效.方法选择本院收治的支原体感染后慢性咳嗽的患儿60例,按随机原则分为对照组和治疗组,每组30例.两组均采用相同的止咳化痰药对症处理.治疗组同时加用孟鲁司特(顺尔宁)睡前口服,每次1片(<6岁用每片4 mg,≥6岁用每片5 mg),每日1次,连续服用4周.于治疗后1、2、3、4周观察咳嗽缓解情况;于治疗后4周取静脉血,采用双抗体夹心酶联免疫吸附试验(ELISA)检测嗜酸粒细胞阳离子蛋白(ECP)和白细胞介素-5(IL-5)水平.结果随着治疗时间的延长,两组咳嗽缓解率均不断增加,且治疗组缓解率明显高于对照组(1周:60.0%比20.0%,2周:83.3%比33.3%,3周:90.0%比53.3%,4周:93.3%比66.7%,均 P<0.05).治疗4周后,两组 ECP 水平均明显降低(均 P<0.05),但治疗组治疗后 ECP(μg/L)水平与对照组比较差异无统计学意义(4.62±1.53比4.03±1.12,P>0.05);对照组 IL-5(ng/L)水平无明显变化(P>0.05),治疗组明显下降,且治疗组下降程度较对照组更显著(42.24±9.44比61.89±11.67,P<0.05).结论孟鲁司特治疗儿童支原体感染后慢性咳嗽能降低气道炎症,缓解咳嗽症状,缩短病程,疗效肯定,值得临床推广.
目的觀察孟魯司特治療兒童支原體感染緻慢性咳嗽的臨床療效.方法選擇本院收治的支原體感染後慢性咳嗽的患兒60例,按隨機原則分為對照組和治療組,每組30例.兩組均採用相同的止咳化痰藥對癥處理.治療組同時加用孟魯司特(順爾寧)睡前口服,每次1片(<6歲用每片4 mg,≥6歲用每片5 mg),每日1次,連續服用4週.于治療後1、2、3、4週觀察咳嗽緩解情況;于治療後4週取靜脈血,採用雙抗體夾心酶聯免疫吸附試驗(ELISA)檢測嗜痠粒細胞暘離子蛋白(ECP)和白細胞介素-5(IL-5)水平.結果隨著治療時間的延長,兩組咳嗽緩解率均不斷增加,且治療組緩解率明顯高于對照組(1週:60.0%比20.0%,2週:83.3%比33.3%,3週:90.0%比53.3%,4週:93.3%比66.7%,均 P<0.05).治療4週後,兩組 ECP 水平均明顯降低(均 P<0.05),但治療組治療後 ECP(μg/L)水平與對照組比較差異無統計學意義(4.62±1.53比4.03±1.12,P>0.05);對照組 IL-5(ng/L)水平無明顯變化(P>0.05),治療組明顯下降,且治療組下降程度較對照組更顯著(42.24±9.44比61.89±11.67,P<0.05).結論孟魯司特治療兒童支原體感染後慢性咳嗽能降低氣道炎癥,緩解咳嗽癥狀,縮短病程,療效肯定,值得臨床推廣.
목적관찰맹로사특치료인동지원체감염치만성해수적림상료효.방법선택본원수치적지원체감염후만성해수적환인60례,안수궤원칙분위대조조화치료조,매조30례.량조균채용상동적지해화담약대증처리.치료조동시가용맹로사특(순이저)수전구복,매차1편(<6세용매편4 mg,≥6세용매편5 mg),매일1차,련속복용4주.우치료후1、2、3、4주관찰해수완해정황;우치료후4주취정맥혈,채용쌍항체협심매련면역흡부시험(ELISA)검측기산립세포양리자단백(ECP)화백세포개소-5(IL-5)수평.결과수착치료시간적연장,량조해수완해솔균불단증가,차치료조완해솔명현고우대조조(1주:60.0%비20.0%,2주:83.3%비33.3%,3주:90.0%비53.3%,4주:93.3%비66.7%,균 P<0.05).치료4주후,량조 ECP 수평균명현강저(균 P<0.05),단치료조치료후 ECP(μg/L)수평여대조조비교차이무통계학의의(4.62±1.53비4.03±1.12,P>0.05);대조조 IL-5(ng/L)수평무명현변화(P>0.05),치료조명현하강,차치료조하강정도교대조조경현저(42.24±9.44비61.89±11.67,P<0.05).결론맹로사특치료인동지원체감염후만성해수능강저기도염증,완해해수증상,축단병정,료효긍정,치득림상추엄.
Objective To investigate the effect of Montelukast on mycoplasma infection induced chronic cough in children. Methods Sixty children with chronic cough after mycoplasma infection were recruited in the study and were randomly divided into control group(30 cases)and treated group(30 cases). Both groups received the same drugs to relieve cough and sputum. Montelukast was exclusively added in the treated group,once a pill/day, the dosage being a 4 mg pill for <6 years and a 5 mg one for ≥ 6 years children. The treatment lasted for 4 weeks. Cough symptom relief was observed 1,2,3 and 4 weeks after treatment. The eosinophil cationic protein(ECP)and interleukin-5(IL-5)levels in venous blood were also determined by enzyme-linked immunosorbent assay(ELISA) 4 weeks after treatment. Results With the prolongation of treatment time,cough symptoms were gradually relieved in both groups,and the relief rates were higher in treated group than those in control group(1 week :60.0% vs. 20.0%,2 weeks :83.3% vs. 33.3%,3 weeks :90.0% vs. 53.3%,4 weeks :93.3% vs. 66.7%,all P<0.05). The ECP(μg/L)level in both groups was reduced obviously after 4 weeks(both P<0.05);the difference in the level after treatment between treated group and control group had no statistic significance(4.62±1.53 vs. 4.03±1.12,P>0.05). The IL-5(ng/L)level was reduced significantly in treated group(P<0.05),but there was no observable change in control group(P>0.05),the difference between the two groups being significant(42.24±9.44 vs. 61.89±11.67,P<0.05). Conclusions Montelukast can significantly reduce bronchial inflammation,relieve the cough symptom, and shorten the course of the chronic cough induced by mycoplasma infection in children. Since its therapeutic effect is confirmed,it is worthwhile to be widely used in clinical practice.
